James R Berenson

Dr. Berenson is the founder of the Institute for Myeloma & Bone Cancer Research (IMBCR) and has specialized in research related to myeloma and metastatic bone disease both in the basic and clinical areas for more than 20 years. He has been involved in many of the major breakthroughs that have brought new treatments for patients with these diseases resulting in both an improvement in the length and quality of their lives.

He serves as a member of the National Institutes of Health - Center for Scientific Review, Clinical Oncology Study Section. He is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. He serves on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society. He also works with many other groups known for their work in multiple myeloma and bone metastases.

After receiving a Bachelor of Science with Distinction from Stanford University, he earned his Doctorate in Medicine from the University of California at San Diego. Dr. Berenson completed his internship and residency in internal medicine at the University of Utah Medical Center and fellowships in hematology/oncology at the University of California at Los Angeles (UCLA). He is certified by the American Board of Internal Medicine in both internal medicine and medical oncology. He has been affiliated most recently with Cedars-Sinai Medical Center in Los Angeles and served as the Director of the Multiple Myeloma & Bone Metastasis Programs in the Department of Medicine, Division of Hematology / Oncology. Dr.Berenson has performed research as a member of the Departments of Medicine and Biological Chemistry at the UCLA School of Medicine and has served as Chief of Medical Oncology and Cancer Research as well as Director of Research at the Greater Los Angeles Veterans Administration Healthcare Systems. Dr.Berenson has authored and co-authored numerous books, articles, and abstracts in journals including Blood, Cancer, Cancer Research, Journal of Clinical Investigation, Journal of Clinical Oncology, New England Journal of Medicine, and Science.

In addition to his research interests in myeloma and metastatic bone disease, he also studies antibodies, T-cell receptors, cytokines, cancer genes, viruses and blood vessel development. Dr.Berenson has also conducted numerous clinical trials related to the treatment of multiple myeloma and metastatic bone disease. Because he is internationally known for his expertise and accomplishments in these areas, he has also been asked to give numerous lectures and organize many meetings both nationally and internationally.

Dr.Berenson has a private practice which specializes in the treatment of patients with myeloma and metastatic bone disease.He is also President and Chief Executive Officer of Oncotherapeutics, Inc., a corporation that conducts clinical trials related to myeloma and metastatic bone disease as well as other cancers throughout the United States. Born and raised in Portland, Oregon, Dr.Berenson is married to Debra. They have two children.